Markets
Tendies
@tendies
Bought ELTP
Shares
up 1.62%
At 0.41, Now 0.42
I just found out that Elite Pharmaceuticals has launched its generic version of Percocet, which could significantly boost their revenues. With the ann...
Read
More
Thesis
I just found out that Elite Pharmaceuticals has launched its generic version of Percocet, which could significantly boost their revenues. With the annual sales for this product hitting around $317 million, I'm optimistic about ELTP's growth potential in the near term.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 35.48%
At 0.31, Exited 0.43
I’m really bullish on ELTP because the current manipulation makes it a great opportunity. With tariffs favoring domestic production and potential buyo...
Read
More
Thesis
I’m really bullish on ELTP because the current manipulation makes it a great opportunity. With tariffs favoring domestic production and potential buyout interest from larger firms like TEVA, the outlook seems solid. I'm looking to hold this as I believe it’ll appreciate significantly once the buyout news breaks.
Go back
Tendies
@tendies
Bought ELTP
Shares
down -31.98%
At 0.47, Exited 0.32
I believe that ELTP is poised for a strong year ahead with their recent launch of generic Vyvanse. As they report record-breaking financials by the en...
Read
More
Thesis
I believe that ELTP is poised for a strong year ahead with their recent launch of generic Vyvanse. As they report record-breaking financials by the end of June, I'm confident that this stock will see significant upward movement in the coming months.
Go back
Tendies
@tendies
Bought ELTP
Shares
down -14.24%
At 0.49, Now 0.42
I'm convinced that ELTP has enormous potential with its upcoming drug approvals and market position in the Generic Adderall space. The company's uniqu...
Read
More
Thesis
I'm convinced that ELTP has enormous potential with its upcoming drug approvals and market position in the Generic Adderall space. The company's unique value proposition and ability to drive sales effectively makes it a solid long-term investment, especially with the recent developments suggesting a strong buyout opportunity.
Go back
Tendies
@tendies
Bought ELTP
Shares
down -5.59%
At 0.52, Exited 0.49
I see strong potential in ELTP as the company is not only profitable but also poised for growth with the recent launch of its generic Vyvanse. With ro...
Read
More
Thesis
I see strong potential in ELTP as the company is not only profitable but also poised for growth with the recent launch of its generic Vyvanse. With robust financials and discussions about potential acquisitions or uplisting, I believe this stock will continue to rise in value, making it a solid pick for the near future.
Go back
Tendies
@tendies
Bought ELTP
Shares
down -3.34%
At 0.52, Exited 0.5
With the recent launch of three new drugs, I believe that Elite Pharmaceuticals is on track for its highest revenue yet. The upcoming earnings will li...
Read
More
Thesis
With the recent launch of three new drugs, I believe that Elite Pharmaceuticals is on track for its highest revenue yet. The upcoming earnings will likely reflect this growth, and I am optimistic about the stock's potential jump post-announcement.
Go back
Tendies
@tendies
Bought ELTP
Shares
down -3.02%
At 0.53, Exited 0.52
I've been holding ELTP and I've noticed it tightening up, which suggests a breakout could be on the horizon. The recent upward movement indicates that...
Read
More
Thesis
I've been holding ELTP and I've noticed it tightening up, which suggests a breakout could be on the horizon. The recent upward movement indicates that there might be potential for significant gains in the upcoming weeks, especially once their new plant comes online.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 0.34%
At 0.5, Exited 0.5
I've just increased my position in ELTP because I'm very optimistic about the upcoming earnings call. With projected revenue growth and the potential ...
Read
More
Thesis
I've just increased my position in ELTP because I'm very optimistic about the upcoming earnings call. With projected revenue growth and the potential for increased analyst coverage, this feels like a strong opportunity, especially if the price remains under $1 post-earnings.
Go back
Tendies
@tendies
Bought ELTP
Shares
down -0.66%
At 0.49, Exited 0.48
I've been evaluating ELTP and given their recent profitability and growth trajectory, especially with the upcoming earnings call, I believe the stock ...
Read
More
Thesis
I've been evaluating ELTP and given their recent profitability and growth trajectory, especially with the upcoming earnings call, I believe the stock is primed for considerable growth in the coming months. With potential upside in the share price, I'm choosing to accumulate more.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 1.03%
At 0.47, Exited 0.48
I've evaluated ELTP based on its existing orders and solid sales team performance. I anticipate the stock could appreciate to the $3.60 to $4.60 range...
Read
More
Thesis
I've evaluated ELTP based on its existing orders and solid sales team performance. I anticipate the stock could appreciate to the $3.60 to $4.60 range in the near future due to its compelling market position and potential drug approvals, making it an attractive buy for a swing trade.
Go back
Tendies
@tendies
Bought ELTP
Shares
down -6.41%
At 0.56, Exited 0.52
I see potential in ELTP due to their recent FDA approvals and market expansion. Despite concerns about product quality, I’m still bullish on the stock...
Read
More
Thesis
I see potential in ELTP due to their recent FDA approvals and market expansion. Despite concerns about product quality, I’m still bullish on the stock because if they can address these issues, it could be a massive win as they capture more market share in the pharmaceutical space.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 10.0%
At 0.5, Exited 0.55
I see a lot of exciting potential in ELTP as we head into 2025. The buzz around it suggests that it's time to get in while the momentum is building, a...
Read
More
Thesis
I see a lot of exciting potential in ELTP as we head into 2025. The buzz around it suggests that it's time to get in while the momentum is building, as I believe it's going to gain serious traction soon.
Go back
Tendies
@tendies
Bought ELTP
Shares
down -1.92%
At 0.61, Exited 0.6
I'm really excited about ELTP's commercial launch. With the upcoming months looking promising, I think this stock is poised for some nice gains as dem...
Read
More
Thesis
I'm really excited about ELTP's commercial launch. With the upcoming months looking promising, I think this stock is poised for some nice gains as demand picks up. Holding through December and January seems like a smart play to me.
Go back
Stonks
@stocks
Bought ELTP
Shares
down -20.97%
At 0.62, Exited 0.49
I'm really confident in ELTP's future, especially with its strong past performance and upcoming projects. With plans for a buyout and up-listing, I se...
Read
More
Thesis
I'm really confident in ELTP's future, especially with its strong past performance and upcoming projects. With plans for a buyout and up-listing, I see this penny stock heading towards $2 or more in the next couple of years, which makes it worth holding heavily in my portfolio.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 19.14%
At 0.52, Exited 0.62
I'm excited about ELTP's recent financial results showing a 33% revenue increase and an impressive 84% rise in operating profits. With their Elite lab...
Read
More
Thesis
I'm excited about ELTP's recent financial results showing a 33% revenue increase and an impressive 84% rise in operating profits. With their Elite label product line gaining traction, I believe the stock is positioned for further growth in the near term.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 30.49%
At 0.51, Exited 0.67
I'm really bullish on ELTP due to their strategic partnerships and upcoming product launches in the generics space. With a focus on high-demand drugs ...
Read
More
Thesis
I'm really bullish on ELTP due to their strategic partnerships and upcoming product launches in the generics space. With a focus on high-demand drugs and a solid revenue increase last year, I see a great opportunity for growth in the near to medium term.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 15.08%
At 0.44, Exited 0.51
With the recent REMS approvals for ELTP’s pain medications like Oxycodone and Methadone, I’m feeling bullish about the stock. This could lead to incre...
Read
More
Thesis
With the recent REMS approvals for ELTP’s pain medications like Oxycodone and Methadone, I’m feeling bullish about the stock. This could lead to increased revenue opportunities, so I’m planning to hold onto my shares for a potential upswing.
Go back
Tendies
@tendies
Shorted ELTP
Shares
up 10.4%
At 0.57, Exited 0.51
I just sold my entire position in ELTP based on insider selling from a senior executive right before earnings. I think the earnings report will likely...
Read
More
Thesis
I just sold my entire position in ELTP based on insider selling from a senior executive right before earnings. I think the earnings report will likely miss, especially with the uncertainty surrounding FDA decisions for vyvanse. I believe we might see a major pullback after the earnings announcement.
Go back
Tendies
@tendies
Bought ELTP
Shares
down -27.66%
At 0.7, Exited 0.51
Despite the recent drop, I see this as a great buy opportunity for ELTP. The fundamentals haven’t changed, and with the upcoming news in November, I b...
Read
More
Thesis
Despite the recent drop, I see this as a great buy opportunity for ELTP. The fundamentals haven’t changed, and with the upcoming news in November, I believe it’s poised for a rebound. If you believe in the company, now’s the time to add to your position.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 18.66%
At 0.48, Exited 0.58
I'm really bullish on ELTP due to its strong pipeline of generic medications and upcoming FDA approvals. The recent news about their international sal...
Read
More
Thesis
I'm really bullish on ELTP due to its strong pipeline of generic medications and upcoming FDA approvals. The recent news about their international sales and a new facility further strengthen my confidence that this stock is primed to rise significantly over the next year.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 9.85%
At 0.44, Exited 0.48
I believe $ELTP is on a solid growth path with great medications in the pipeline and expansion plans. I'm planning to hold my position for at least 1-...
Read
More
Thesis
I believe $ELTP is on a solid growth path with great medications in the pipeline and expansion plans. I'm planning to hold my position for at least 1-2 years, expecting the stock to hit $3+ easily, which makes this a strong long-term investment.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 46.62%
At 0.4, Exited 0.58
I'm really excited about ELTP after the news of their generic Adderall approval. This could seriously boost their market presence, especially with the...
Read
More
Thesis
I'm really excited about ELTP after the news of their generic Adderall approval. This could seriously boost their market presence, especially with the potential European expansion on the horizon. With multiple launches expected soon, I'm convinced this stock is set to increase significantly.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 3.59%
At 0.37, Exited 0.39
I've got a strong feeling about ELTP, especially with the upcoming catalysts including facility approvals and multiple drug releases. The potential ma...
Read
More
Thesis
I've got a strong feeling about ELTP, especially with the upcoming catalysts including facility approvals and multiple drug releases. The potential market value alone makes this stock a potential goldmine, and with the CEO focusing on significant projects, it's time to get in and hold for some nice gains.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 24.34%
At 0.31, Exited 0.39
I just added to my position in ELTP because the growth metrics are impressive and the revenue is expected to increase as they roll out more products. ...
Read
More
Thesis
I just added to my position in ELTP because the growth metrics are impressive and the revenue is expected to increase as they roll out more products. With a potential billion dollar market cap in two years, I see significant upside ahead.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 46.18%
At 0.28, Exited 0.4
I'm really convinced that $ELTP is set to grow significantly due to their strong market penetration strategy and upcoming drug launches. With a solid ...
Read
More
Thesis
I'm really convinced that $ELTP is set to grow significantly due to their strong market penetration strategy and upcoming drug launches. With a solid track record of profitability and expanding capacity, this company looks poised for substantial revenue growth in the near future.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 119%
At 0.28, Exited 0.6
Considering the significant increase in revenues and operating profits, along with the unusual short interest at a lower price, I believe Elite Pharma...
Read
More
Thesis
Considering the significant increase in revenues and operating profits, along with the unusual short interest at a lower price, I believe Elite Pharmaceuticals is poised for growth. The large volume without much price movement suggests strong underlying interest and potential for a future rise in share price.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 9.81%
At 0.29, Exited 0.31
With multiple high-revenue generic medications pending launch and FDA approvals expected soon, I believe ELTP is poised for substantial profit and rev...
Read
More
Thesis
With multiple high-revenue generic medications pending launch and FDA approvals expected soon, I believe ELTP is poised for substantial profit and revenue growth. This positions them well for a potential move to NASDAQ or M&A activity, making it a promising swing trade opportunity.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 203%
At 0.2, Exited 0.61
As this stock gains more exposure with ongoing product approvals and FDA support, I believe ELTP will see significant growth. The potential risks are ...
Read
More
Thesis
As this stock gains more exposure with ongoing product approvals and FDA support, I believe ELTP will see significant growth. The potential risks are minimal and standard for the industry, making it a solid long-term investment with high upside potential.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 241%
At 0.2, Exited 0.67
Elite Pharmaceuticals has several key products slated for release and significant FDA approvals anticipated in the next few months. With strong revenu...
Read
More
Thesis
Elite Pharmaceuticals has several key products slated for release and significant FDA approvals anticipated in the next few months. With strong revenue growth and a solid financial position, I believe ELTP is well-positioned for substantial gains, especially given the potential for M&A or a NASDAQ move.
Go back
Tendies
@tendies
Bought ELTP
Shares
up 25.17%
At 0.19, Exited 0.24
With Elite Pharmaceuticals experiencing a 109% revenue surge in Q1 FY2025, I believe the stock is poised for a strong upward movement, making it a goo...
Read
More
Thesis
With Elite Pharmaceuticals experiencing a 109% revenue surge in Q1 FY2025, I believe the stock is poised for a strong upward movement, making it a good opportunity for a swing trade.
Go back
